(Q44471067)

3 December 2017

title

A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer (English)

1 reference

3 December 2017

1 reference

Sanjay Goel

1

1 reference

3 December 2017

Scott Wadler

2

1 reference

3 December 2017

Anthony Hoffman

3

1 reference

3 December 2017

Fabio Volterra

4

1 reference

3 December 2017

Cheryl Baker

5

1 reference

3 December 2017

Elliot Nazario

6

1 reference

3 December 2017

Percy Ivy

7

1 reference

3 December 2017

Alyson Silverman

8

1 reference

3 December 2017

Sridhar Mani

9

1 reference

3 December 2017

publication date

1 February 2003

1 reference

Investigational New Drugs

3 December 2017

published in

1 reference

3 December 2017

volume

21

1 reference

3 December 2017

issue

1

1 reference

3 December 2017

page(s)

103-107

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

3 December 2017

cites work

1 reference

12 December 2020

Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin

1 reference

12 December 2020

Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents

1 reference

12 December 2020

Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days

1 reference

12 December 2020

Production, isolation and structure determination of novel fluoroindolocarbazoles from Saccharothrix aerocolonigenes ATCC 39243.

1 reference

12 December 2020

In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.

1 reference

12 December 2020

DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin

1 reference

12 December 2020

Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Water soluble derivatives of rebeccamycin

1 reference

12 December 2020

The biosynthetic origins of rebeccamycin

1 reference

12 December 2020

Production and biological activity of rebeccamycin, a novel antitumor agent.

1 reference

12 December 2020

Conformational Control in the Rebeccamycin Class of Indolocarbazole Glycosides.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1022980613420

1 reference

Dimensions Publication ID

3 December 2017

1030674861

0 references

1 reference